Benign Prostatic Hyperplasia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Aug 2019| TMR1760A| Transparency

Report Highlights

Benign Prostatic Hyperplasia Treatment Market - Scope of the Study

Transparency Market Research (TMR), in its recently published research report, quantifies the growth of the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027. This exclusive research report on the global benign prostatic hyperplasia treatment market offers a detailed overview of the benign prostatic hyperplasia treatment market, uncovering significant aspects and segmentations based on numerous parameters. This comprehensive research report also talks about the research methodologies being adopted in order to estimate precise market numbers. This detailed business guide also includes relevant charts and tables, in order to enable stakeholders get an incisive outlook of the benign prostatic hyperplasia treatment market for the forecast period.

This statistical business report analyzes, at length, crucial insights obtained by this exclusive study. With the aid of rare and distinguished insights enumerated in this comprehensive research report, stakeholders in the benign prostatic hyperplasia treatment market can form business growth strategies to gain an upper hand over their competitors. Various factors accounted for the benign prostatic hyperplasia treatment market’s upward growth trajectory are discussed at length in this research report. Additionally, the research report identifies and explains the key drivers, threats, restraints, and opportunities present in the benign prostatic hyperplasia treatment market.

This broad study of the global benign prostatic hyperplasia treatment market assesses the growth drivers and restraints at length. This exhaustive study of important factors can aid market players in understanding the challenges present in the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027. The detailed research report gauges the bargaining power of buyers and suppliers, threats arising from new market entrants and substitutes, and the degree of competition present in the benign prostatic hyperplasia treatment market. Influence exerted on the benign prostatic hyperplasia treatment market by the government policies is also discussed in this research report.

Benign Prostatic Hyperplasia Treatment Market - Segmentation

This comprehensive research report encompasses the technological advancements and recent trends to gain a better perspective of the growth of the benign prostatic hyperplasia treatment market. In order to aid market players in having a precise market approach, our analysts have bifurcated the benign prostatic hyperplasia treatment market into key segments - treatment, end user, and region. Key segments of the benign prostatic hyperplasia treatment market are as mentioned below:

Benign Prostatic Hyperplasia Treatment Market - Key Questions Answered

This comprehensive research report analyzes and answers crucial questions related to the growth of the benign prostatic hyperplasia treatment market during the forecast period. Some of the key questions answered in this study are as follows:

What are the key developments and important market shifts expected to be observed in the benign prostatic hyperplasia treatment market during the forecast period of 2019-2027?
What are the key strategies followed by market participants functioning in the benign prostatic hyperplasia treatment market?
What are some of the important recent developments that the new market participants should look at?
Which treatment will be the top-selling one in the benign prostatic hyperplasia treatment market?
Benign Prostatic Hyperplasia Treatment Market - Research Methodology

The research approach taken by analysts at Transparency Market Research (TMR) includes a robust methodology for obtaining key insights into the benign prostatic hyperplasia treatment market for the forecast period of 2019-2027. Interviews were conducted with important market participants, opinion leaders, vendors, distributors, and industry experts. In addition to this, a detailed secondary study of company websites, industry associations, marketing collaterals, and government statistics is carried out.

  • Table 1 : Prostate Cancer Therapeutics : Pipeline Analysis – Phase III (1/2)
  • Table 2 : Prostate Cancer Therapeutics : Pipeline Analysis – Phase III (2/2)
  • Table 3 : Prostate Cancer Therapeutics : Pipeline Analysis – Phase II (1/2)
  • Table 4 : Prostate Cancer Therapeutics : Pipeline Analysis – Phase II (2/2)
  • Table 5 : Prostate Cancer Therapeutics : Pipeline Analysis – Phase I
  • Table 6 : 2015 Patient Population Break Down
  • Table 7 : Number of Surgeries (Unit Procedures) Performed in United States (2018)
  • Table 8 : Summary of Current BPH Treatments in U.S.
  • Table 9 : Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
  • Table 10 : Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027
  • Table 11 : Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2027
  • Table 12 : Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2027
  • Table 13 : Global Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Region, 2016–2026
  • Table 14 : North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country, 2016–2026
  • Table 15 : Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
  • Table 16 : Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027
  • Table 17 : Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2027
  • Table 18 : North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2016–2026
  • Table 19 : Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
  • Table 20 : Europe Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
  • Table 21 : Europe Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027
  • Table 22 : Europe Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2027
  • Table 23 : Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
  • Table 24 : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
  • Table 25 : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
  • Table 26 : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027
  • Table 27 : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2027
  • Table 28 : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
  • Table 29 : Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
  • Table 30 : Latin America Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
  • Table 31 : Latin America Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027
  • Table 32 : Latin America Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2027
  • Table 33 : Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
  • Table 34 : Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
  • Table 35 : Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
  • Table 36 : Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2027
  • Table 37 : Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, by Minimally Invasive Surgeries, 2017–2027
  • Table 38 : Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
  • Figure 1 : Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) Forecast, 2017–2027
  • Figure 2 : Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Treatment, 2018
  • Figure 3 : Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Drug Class, 2018
  • Figure 4 : Global Benign Prostatic Hyperplasia Treatment Market Value Share, by End-user, 2018
  • Figure 5 : Global Benign Prostatic Hyperplasia Treatment Market Value Share, by Minimally Invasive Surgery, 2018
  • Figure 6 : Global Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • Figure 7 : Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Drug Class, 2017–2027
  • Figure 8 : Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Minimally Invasive Surgeries, 2017–2027
  • Figure 9 : Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Laser Therapy, 2017–2027
  • Figure 10 : Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Others, 2017–2027
  • Figure 11 : Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment, 2019–2027
  • Figure 12 : Global Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • Figure 13 : Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Hospitals, 2017–2027
  • Figure 14 : Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Ambulatory Surgical Centers, 2017–2027
  • Figure 15 : Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Specialty Clinics, 2017–2027
  • Figure 16 : Global Benign Prostatic Hyperplasia Treatment Market Revenue, by Others, 2017–2027
  • Figure 17 : Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user, 2019–2027
  • Figure 18 : Global Benign Prostatic Hyperplasia Treatment Market Value Share (%), by Region, 2018 and 2026
  • Figure 19 : Global Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Region, 2018–2026
  • Figure 20 : North America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 21 : North America Benign Prostatic Hyperplasia Treatment Market Value Share, by Country, 2017 and 2026
  • Figure 22 : North America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country, 2018–2026
  • Figure 23 : North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2017 and 2026
  • Figure 24 : North America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2018–2026
  • Figure 25 : North America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2017 and 2026
  • Figure 26 : North America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2018–2026
  • Figure 27 : Europe Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027
  • Figure 28 : Europe Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • Figure 29 : Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
  • Figure 30 : Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • Figure 31 : Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019–2027
  • Figure 32 : Europe Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • Figure 33 : Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019–2027
  • Figure 34 : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027
  • Figure 35 : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • Figure 36 : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
  • Figure 37 : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • Figure 38 : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019–2027
  • Figure 39 : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • Figure 40 : Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019–2027
  • Figure 41 : Latin America Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027
  • Figure 42 : Latin America Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • Figure 43 : Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
  • Figure 44 : Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • Figure 45 : Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019–2027
  • Figure 46 : Latin America Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • Figure 47 : Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019–2027
  • Figure 48 : Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027
  • Figure 49 : Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
  • Figure 50 : Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
  • Figure 51 : Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
  • Figure 52 : Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness, by Treatment, 2019–2027
  • Figure 53 : Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Value Share Analysis, by End-user, 2018 and 2027
  • Figure 54 : Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness, by End-user, 2019–2027
  • Figure 55 : Global Benign Prostatic Hyperplasia Treatment Devices Market Share Analysis, by Company, 2018
  • Figure 56 : GlaxoSmithKline plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2018
  • Figure 57 : GlaxoSmithKline plc. R&D Expenses and Selling, General and Administration Expenses (US$ Bn) - Company Level, 2015–2018
  • Figure 58 : GlaxoSmithKline plc. Breakdown of Net Sales, by Region/Country (Company Level), 2018
  • Figure 59 : GlaxoSmithKline plc. Breakdown of Net Sales, by Business Segment (Overall Company Level), 2018
  • Figure 60 : Sanofi R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 61 : Sanofi Breakdown of Net Sales (%), by Region/Country, 2018
  • Figure 62 : Sanofi Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2018
  • Figure 63 : Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018
  • Figure 64 : Pfizer, Inc. Breakdown of Net Sales, by Region/Country, 2018
  • Figure 65 : Pfizer, Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2015–2018
  • Figure 66 : Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2018
  • Figure 67 : Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
  • Figure 68 : Teva Pharmaceutical Industries Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
  • Figure 69 : Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2018
  • Figure 70 : Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Operating Segment, 2017
  • Figure 71 : Abbott Laboratories Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2018
  • Figure 72 : Abbott Laboratories R&D Intensity and Sales & Marketing Intensity – Company Level, 2016–2018
  • Figure 73 : Abbott Laboratories Breakdown of Net Sales, by Segment, 2018
  • Figure 74 : Abbott Breakdown of Net Sales (%), by Country/Sub-region, 2018
  • Figure 75 : Allergan plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018
  • Figure 76 : Allergan plc Breakdown of Net Sales (%), by Geography, 2018
  • Figure 77 : Allergan plc R&D Expenses and Marketing & Sales Intensity (%) 2016–2018
  • Figure 78 : Allergan plc Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 79 : Endo Pharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018
  • Figure 80 : Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Region, 2016
  • Figure 81 : Endo Pharmaceuticals, Inc. total Acquisition-related and Integration Items, Expenses in 2016–2018
  • Figure 82 : Endo Pharmaceuticals, Inc. Breakdown of Net Sales (%), by Specialty Products, 2018
  • Figure 83 : Boehringer Ingelheim GmbH Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2018
  • Figure 84 : Boehringer Ingelheim GmbH Breakdown of Net Sales, by Region (Company Level), 2018
  • Figure 85 : Boehringer Ingelheim GmbH Breakdown of Net Sales, by Business and Business Segment Level, 2017
  • Figure 86 : Boehringer Ingelheim GmbH R&D Expenditure (US$ Mn), 2016–2018
  • Figure 87 : Merck & Co., Inc. Break-up of Net Sales, by Region, 2017
  • Figure 88 : Merck & Co., Inc. Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018
  • Figure 89 : Merck & Co., Inc. R&D Intensity (%) - Company Level or Segment Level, 2014–2017
  • Figure 90 : Asahi Kasei Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
  • Figure 91 : Asahi Kasei Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
  • Figure 92 : Asahi Kasei Corporation Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 93 : Astellas Pharma, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2018
  • Figure 94 : Astellas Pharma, Inc. Breakdown of Net Sales (%), by Region, 2016
  • Figure 95 : Astellas Pharma, Inc. R&D expenses (US$ Bn) in 2016–2018
  • Figure 96 : Astellas Pharma, Inc. Breakdown of Net Sales (%), by Main Products, 2018
  • Figure 97 : Teleflex Incorporated, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
  • Figure 98 : Teleflex Incorporated, Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 99 : Teleflex Incorporated, Breakdown of Net Sales (%), by Geography, 2018
  • Figure 100 : Boston Scientific Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018
  • Figure 101 : Boston Scientific Corporation Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 102 : Boston Scientific Corporation Breakdown of Net Sales (%), by Country, 2017
  • Figure 103 : Boston Scientific Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018
  • Figure 104 : Olympus Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2018
  • Figure 105 : Olympus Corporation Breakdown of Net Sales (%), by Region, 2018
  • Figure 106 : Olympus Corporation Breakdown of Net Sales (%), by Medical Business Segment, 2018

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report